high
suscept
elderli
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
indic
crucial
protect
elderli
variou
strategi
age
balbc
mice
display
high
suscept
sarscov
valuabl
platform
evalu
strategi
sarscov
infect
studi
confirm
valid
model
use
variou
method
verifi
equin
antisarscov
f
ab
prevent
age
anim
sarscov
infect
therapeut
set
treatment
antisarscov
f
ab
decreas
viral
load
sever
thousand
fold
lung
thu
antibodi
potenti
candid
treatment
elderli
patient
suffer
sar
incid
sever
acut
respiratori
syndrom
sar
control
widespread
infect
reemerg
sinc
initi
outbreak
howev
mysteri
anim
origin
strong
infect
necessit
studi
control
replic
affect
individu
retrospect
studi
shown
elderli
patient
sar
experienc
high
mortal
morbid
suggest
suscept
sarsassoci
coronaviru
sarscov
could
correl
age
base
upon
observ
robert
colleagu
establish
age
mous
model
longer
cours
viru
replic
sever
patholog
chang
respiratori
tract
observ
young
mice
indic
appropri
anim
model
parallel
age
human
term
suscept
sarscov
adopt
antibodi
transfer
use
prevent
treat
infecti
diseas
long
histori
thu
provid
candid
strategi
protect
host
sarscov
infect
yo
colleagu
found
infus
convalesc
plasma
result
benefici
clinic
outcom
sar
patient
subbarao
et
al
verifi
passiv
transfer
sarscov
specif
antisera
reduc
pulmonari
viral
titr
mice
infect
sarscov
indic
hyperimmun
sera
sarscov
could
protect
viral
infect
hand
equin
antiserum
success
use
control
variou
viru
infect
rabi
hbv
hiv
base
evid
feasibl
equin
antibodi
use
human
diseas
develop
equin
antisarscov
f
ab
provid
excel
protect
viru
infect
previous
test
balbc
model
howev
vigor
test
anim
model
must
conduct
clinic
trial
insur
efficaci
studi
confirm
age
mous
model
use
addit
assess
method
previous
report
test
equin
antisarscov
antibodi
model
prevent
therapeut
set
expect
antibodi
exhibit
complet
prevent
effect
consider
therapeut
role
sarscov
infect
anim
model
provid
strong
evid
potenti
applic
antibodi
futur
clinic
test
sarscov
strain
genbank
access
number
isol
feb
mar
maintain
institut
microbiolog
epidemiolog
amm
china
propag
vero
cell
viru
releas
infect
cell
three
freezethaw
cycl
titr
determin
tissu
cultur
infect
dose
tcid
ml
oper
sarscov
perform
biosafeti
level
laboratori
evalu
suscept
age
balbc
mice
month
sarscov
infect
follow
light
anesthet
isofluran
tcid
sarscov
particl
suspens
administ
intra
nasal
anim
day
four
mice
group
sacrif
day
post
infect
pi
lung
experiment
anim
remov
homogen
wv
suspens
leibovitz
medium
invitrogen
viral
titr
copi
homogen
determin
use
cytopath
effect
cpe
taqman
realtim
quantit
rtpcr
qrtpcr
assay
describ
patholog
local
sarscov
lung
infect
anim
determin
patholog
observ
immunohistochemistri
ihc
describ
investig
prevent
role
equin
antisarscov
f
ab
sarscov
infect
follow
anesthet
age
mice
inject
intra
periton
ip
antisarscov
f
ab
mgkg
bodi
weight
nonimmun
normal
hors
antibodi
mgkg
bodi
weight
neg
control
day
day
viral
infect
twentyfour
hour
later
day
age
mice
challeng
tcid
sarscov
sacrif
day
pi
viral
titr
copi
local
well
patholog
chang
infect
anim
lung
determin
cpe
qrtpcr
ihc
patholog
observ
method
evalu
therapeut
role
antisarscov
f
ab
sarscov
infect
age
mice
anim
receiv
ip
tcid
sarscov
day
follow
ip
inject
f
ab
mgkg
bodi
weight
normal
hors
antibodi
mgkg
lack
neutral
activ
neg
control
day
pi
viral
titr
copi
local
well
patholog
chang
infect
anim
lung
determin
day
pi
respect
realtim
quantit
taqman
pcr
cpe
assay
use
determin
sarscov
titr
copi
lung
sarscov
infect
mock
infect
age
mice
describ
previous
number
sarscov
n
gene
copi
determin
qpcr
cpe
assay
conduct
cultur
vero
cell
age
mice
anesthet
isofluran
euthan
cervic
disloc
indic
day
follow
viru
administr
antisarscov
f
ab
inject
lung
tissu
fix
neutral
buffer
formalin
embed
paraffin
block
process
routin
histolog
ihc
avidinbiotin
peroxidas
complex
techniqu
abc
detect
describ
subbarao
et
al
ihc
purifi
equin
antisarscov
igg
use
detect
antibodi
dab
chromogen
substrat
statist
analys
perform
anova
multipl
comparison
scheff
student
test
graph
repres
mean
sem
viru
titr
increas
day
pi
peak
tcid
g
lung
tissu
day
pi
fig
titr
sustain
high
level
day
pi
tcid
g
decreas
rapidli
thereaft
undetect
level
day
pi
fig
similar
observ
robert
qrtpcr
assay
verifi
cours
viral
titr
chang
fig
day
pi
viru
experienc
peak
copi
g
lung
tissu
howev
day
pi
viral
titr
undetect
cpe
assay
sever
thousand
copi
viru
could
still
detect
qrtpcr
fig
sever
patholog
concord
amount
viru
lung
cours
patholog
chang
observ
system
day
pi
patholog
chang
mild
lung
tissu
construct
roughli
remain
normal
except
small
vessel
dilat
congest
edema
alveolar
space
fig
arrow
compar
normal
mous
lung
fig
viral
invas
bronchial
epitheli
cell
less
extent
alveolar
epitheli
cell
adjac
bronchi
observ
fig
day
pi
larg
degre
inflammatori
cell
infiltr
mainli
involv
mononuclear
cell
lymphocyt
around
bronchi
fig
arrow
observ
focal
hemorrhag
around
small
vessel
fig
arrowhead
interstiti
pneumonia
shed
bronchial
epitheli
cell
bronchial
lumen
fig
arrow
f
addit
bronchial
epitheli
cell
alveolar
epitheli
cell
infect
extens
fig
day
pi
consider
inflammatori
cell
infiltr
surround
bronchi
shed
epitheli
cell
diffus
blood
cell
bronchial
lumen
observ
fig
arrow
arrowhead
obviou
effus
bronchial
lumen
well
interstiti
pneumonia
becom
sever
observ
day
pi
fig
larg
viral
load
also
observ
anim
lung
day
fig
day
appear
appar
focal
consolid
fig
arrowhead
focal
necrosi
lung
accompani
consider
inflammatori
cell
infiltr
around
bronchi
small
vessel
fig
arrow
howev
day
amount
viru
diminish
markedli
small
amount
viru
could
observ
around
bronchi
fig
day
consolid
obviou
observ
day
fig
arrow
accompani
focal
necrosi
inflammatori
cell
infiltr
moder
interstiti
pneumonia
still
evid
effus
bronchial
lumen
fig
howev
almost
viru
could
observ
day
fig
result
experi
demonstr
viral
titr
virusinocul
anim
lung
highest
day
pi
inject
indic
amount
equin
antisarscov
f
ab
mice
minu
challeng
tcid
sarscov
day
investig
protect
role
antibodi
viru
infect
day
pi
whether
protect
role
antibodi
dosedepend
cpe
assay
show
mgkg
bodi
weight
antibodi
could
complet
neutral
viru
inocul
anim
lung
fig
even
half
effect
dosag
mgkg
antibodi
provid
remark
protect
effect
fig
contrast
inject
nonimmun
normal
equin
f
ab
mgkg
protect
age
mice
sarscov
infect
similar
viru
posit
control
fig
accordingli
qrtpcr
assay
also
demonstr
mgkg
bodi
weight
antibodi
could
complet
clear
inocul
viru
experiment
lung
could
detect
sarscov
n
gene
lung
homogen
dose
fig
similar
observ
treatment
gkg
bodi
weight
antibodi
result
decreas
viru
load
inocul
anim
lung
fig
control
group
could
still
detect
copi
n
gene
differ
observ
viru
posit
control
group
fig
therapeut
role
equin
antisarscov
antibodi
sarscov
infect
whether
role
antibodi
dosedepend
investig
age
mous
model
age
mous
inocul
tcid
sarscov
day
receiv
ip
inject
indic
dose
f
ab
day
halflif
prepar
f
ab
fragment
h
determin
rat
data
submit
measur
therapeut
role
antibodi
day
pi
equin
neutral
antibodi
administ
viru
inocul
mgkg
antibodi
could
reliev
patholog
lesion
viral
load
anim
lung
panel
day
pi
compar
viru
control
panel
day
anim
lung
show
mild
moder
interstiti
pneumonia
lung
consolid
morpholog
structur
lung
roughli
normal
panel
cpe
assay
indic
mgkg
f
ab
could
exert
signific
therapeut
effect
inhibit
sarscov
infect
anim
protect
dose
sarscov
specif
antibodi
experienc
markedli
decreas
viral
load
lung
compar
neg
antibodi
control
p
b
fig
expect
therapeut
effici
kind
antibodi
day
similar
day
fig
contrast
neg
antibodi
control
nonimmun
equin
f
ab
provid
neutral
effect
viru
fig
qrtpcr
assay
confirm
result
cpe
assay
fig
dose
mgkg
f
ab
fragment
could
partial
significantli
decreas
viral
copi
infect
anim
lung
fold
compar
untreat
anim
fig
robert
establish
age
mous
model
infect
sarscov
urbani
isol
use
patholog
observ
cpe
assay
age
mous
model
studi
extens
employ
addit
method
assess
verifi
age
mous
model
abl
infect
age
balbc
mice
sarscov
strain
inocul
could
demonstr
viru
replic
effect
lung
infect
anim
use
cpe
assay
observ
rapid
viru
propag
day
pi
peak
day
pi
tcid
g
thereaft
diminish
gradual
howev
still
sustain
high
titr
tcid
day
pi
similar
report
robert
quantit
pcr
result
show
express
pattern
viral
n
gene
parallel
viral
titr
chang
confirm
result
cpe
assay
though
fail
detect
viru
present
day
pi
use
cpe
assay
qrtpcr
show
thousand
copi
viru
lung
anim
fig
could
reflect
sensit
differ
cpe
realtim
rtpcr
assay
cpe
assay
absolut
quantit
method
thu
provid
concret
viru
number
certain
sampl
hand
taqman
fluoresc
qpcr
assay
detect
even
singl
copi
gene
thu
provid
detail
molecular
mechan
sarsrel
pathogenesi
evalu
variou
interven
strategi
cpe
method
therefor
studi
demonstr
use
qrtpcr
cpe
assay
accur
determin
viru
replic
allow
us
establish
model
sarscov
infect
surprisingli
robert
observ
ill
sarscov
infect
mice
studi
could
observ
symptom
develop
relat
sarscov
infect
age
mice
specul
may
relat
observ
calcul
method
clinic
diseas
surround
factor
feed
sinc
observ
bodi
weight
normal
control
mice
could
increas
decreas
g
oneweek
observ
concord
observ
robert
found
definit
patholog
chang
lung
infect
anim
furthermor
also
systemat
defin
patholog
chang
infect
anim
lung
typic
patholog
chang
interstiti
pneumonia
larg
amount
viru
infect
bronchi
epitheli
alveolar
cell
fig
multipl
focal
lung
consolid
viru
titr
began
diminish
fig
compar
normal
mous
control
fig
b
two
major
patholog
chang
similar
observ
patient
sar
although
detail
tissu
studi
sarscov
infect
patient
lung
perform
base
symptom
sign
indirect
evid
includ
radiograph
featur
partial
direct
evid
includ
throat
wash
autopsi
appear
patholog
cours
infect
similar
observ
age
mice
thu
even
though
detect
evid
diseas
develop
infect
mice
detail
tissu
studi
report
support
valid
age
mice
model
importantli
close
correl
degre
patholog
chang
viru
titr
viru
copi
age
mous
model
indic
mous
model
serv
credibl
system
investig
effect
variou
intervent
sarscov
infect
recent
studi
humor
immun
respons
sar
patient
indic
patient
longer
cours
ill
show
lower
neutral
antibodi
respons
patient
shorter
ill
durat
indic
neutral
antibodi
patient
play
pivot
role
sarscov
clearanc
vivo
accordingli
gener
equin
antisarscov
f
ab
shown
signific
protect
sarscov
infect
young
balbc
mous
model
complet
neutral
viru
infect
age
mous
achiev
mgg
bodi
weight
antibodi
prevent
set
fig
addit
protect
anim
show
patholog
chang
lung
data
shown
similar
result
also
observ
young
mice
receiv
compar
amount
equin
antibodi
even
though
examin
therapeut
role
antibodi
young
mice
due
short
infect
endur
day
achiev
great
success
use
antibodi
treat
sarscov
infect
age
mice
longer
infect
endur
day
fig
level
protect
observ
decreas
viral
load
although
complet
remark
consid
circul
antibodi
neutral
extracellular
sarscov
result
also
suggest
therapeut
set
might
necessari
combin
passiv
antibodi
transfer
method
antivir
drug
vaccin
ideal
immunoglobulin
adopt
transfer
would
autolog
homolog
origin
lowest
antiantibodi
respons
human
mab
taken
good
candid
respect
howev
issu
low
mab
yield
need
overcom
use
clinic
polyclon
immunoglobulin
surmount
obstacl
antibodi
product
anoth
potenti
advantag
use
polyclon
antibodi
broad
antigen
coverag
reduc
likelihood
emerg
escap
mutant
among
variou
heterolog
antibodi
approv
equin
antibodi
one
appeal
choic
view
conveni
hors
feed
serum
avail
time
equin
antibodi
treatment
approach
offer
advantag
monoclon
antibodi
spite
avail
human
human
mab
antisarscov
research
equin
antibodi
still
attract
candid
prevent
treatment
sar
patient
one
potenti
problem
equin
immunoglobulin
treatment
immunogen
variou
measur
taken
reduc
immunogen
toler
level
remov
fc
fragment
experiment
data
submit
monkey
receiv
intraven
inject
truncat
immunoglobulin
remov
fc
fragment
show
mild
stimul
immun
respons
anim
subject
surviv
inject
motiv
host
secondari
lymphoid
organ
spleen
lymph
node
recov
week
post
inject
withdraw
sinc
host
antif
ab
antibodi
appear
week
post
f
ab
administr
submit
data
almost
complet
neutral
extracellular
viru
applic
antibodi
inhibit
normal
tissu
infect
shown
studi
thu
prevent
transmiss
allow
host
immun
system
clear
remain
viru
provid
chanc
intervent
strategi
antivir
drug
rnai
vaccin
ultim
elimin
viru
form
host
summari
establish
verifi
age
mous
model
confirm
parallel
patholog
chang
pattern
occur
older
human
patient
suffer
sar
importantli
equin
polyclon
antibodi
use
studi
exhibit
excel
therapeut
effect
post
viru
exposur
togeth
proven
protect
role
sarscov
infect
young
mice
provid
strong
evid
therapeut
applic
antibodi
treatment
prevent
sar
